Cancer
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
Roche stakes $1 billion in cancer gene research firm
January 12, 2015Research and Development, Sales and Marketing Cancer, Foundation Medicine, Genentech, Roche, genomics, jp morgan
Roche has announced a huge billion-dollar investment in the cancer genomics research firm Foundation Medicine. Timed with the beginning of …
Late-stage failure for Otsuka and GW cancer pain drug
January 9, 2015Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
NHS plans bashed over cancer and heart disease
December 24, 2014Research and Development, Sales and Marketing Cancer, England, NHS, Simon Stevens, funding, heart
Hundreds of healthcare experts have signed an open letter to NHS chief executive Simon Stevens calling for him to scrap …
Merck acquires Swiss firm OncoEthix
December 19, 2014Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab
Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …
Roche dealt with two late-stage blows
December 19, 2014Sales and Marketing Alzheimer's, Alzheimer’s, Cancer, Kadcyla, Perjeta, Roche, Xeloda, trastuzumab emtansine
Swiss giant Roche’s breast cancer treatment Kadcyla has failed to meet its primary endpoint and its investigational Alzheimer’s treatment trial …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
Lilly’s lung cancer drug sees FDA approval
December 17, 2014Sales and Marketing BMS, Cancer, FDA, NSCLC, cyramza, docetaxel, lilly, opdivo, ramucirumab
Eli Lilly’s lung cancer drug Cyramza (ramucirumab) has been shown the green light by the US Food and Drug Administration …
Celgene UK: market access is a complex business
December 15, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abraxane, CDF, Cancer, Celgene, PPRS, Revlimid, market access, sam pierce
Being a firm that specialises in cancer drugs, Celgene UK is no stranger to England’s notoriously rigorous approach to expensive …
Antibiotic resistance could kill 10 million a year
December 11, 2014Research and Development, Sales and Marketing Antibiotics, Cancer, KPMG, Merck, david cameron, rand
Antibiotic-resistant bacteria will kill an extra 10 million people a year by 2050 if the problem is not tackled soon, …
Labour to extend cancer drugs funding if elected
December 10, 2014Research and Development, Sales and Marketing CDF, Cancer, Labour, NHS, NICE, andy burnham, election
Labour has committed to continuing the Cancer Drugs Fund system under the guise of a new £330 million ‘Cancer Treatment …
Analysis finds no Actos bladder cancer link
December 8, 2014Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2
A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …
CRUK and AZ collaborate on cancer screening
November 28, 2014Research and Development, Sales and Marketing AstraZeneca, CRUK, Cambridge, Cancer, Cancer Research UK, MRC
Cancer Research UK (CRUK) scientists are to be given access to drug discovery facilities at AstraZeneca’s Cambridge site as part …
Cell Medica gets £50 million funding
November 26, 2014Research and Development, Sales and Marketing CMD-003, Cancer, Imperial Innovations, Invesco Perpetual, Woodford Investment Management, celk medica
Cellular immunotherapy development firm Cell Medica has confirmed the completion a £50 million investment round from key backers to progress …
NICE aims for earlier cancer diagnosis
November 20, 2014Sales and Marketing Cancer, England, NHS, NICE, OECD, UK, baker
NICE is updating its guidance in a bid to help doctors spot the signs and symptoms of cancer as part …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
